Compare AbbVie Inc (ABBV) vs McDonald's Corp (MCD) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

McDonald's (MCD) trades at $279.5, down 0.4% on the day, as the stock navigates a challenging consumer environment. The company reported solid Q1 2026 earnings that beat expectations, with revenue reaching $26.89B in 2025 and a robust net income margin of 31.62%. Technical analysis shows a bullish overall signal despite mixed moving averages, with key support at $275 and resistance at $282. Recent news highlights the company's new 'McDonald's>NEXT' growth strategy focused on automation and menu innovation to win back customers.

The outlook for MCD is cautiously optimistic, supported by strong analyst consensus (58% Buy rating) and a $325.50 price target implying significant upside. Investment opportunities include the company's durable franchise model, consistent dividend payments, and strategic initiatives to improve operations. Key risks involve persistent inflationary pressures on franchisee margins, intense competition in the value segment, and execution challenges of the new growth strategy amid economic uncertainty.